0:00Welcome to Base by Base, the paper cast that brings genomics to you wherever you are. Thanks for listening, and don't forget to follow and rate us in your podcast app. So today, we're diving into one of the uh, most persistent mysteries in immuno-on-called way.
0:14It's this paradox of the invincible tumor. We know CD 8 plus T cells are the immune systems, you know, precision fighters. They're essential for clearing cancer, but so often in solid tumors, they just stall out, the therapy fails.
0:29And it really comes down to a fundamental physical problem. We've known for years from imaging study that, for anti-tumor immunity to work, you need physical proximity. The T cells have to get right up close.
0:40Exactly. They have to be within, say, 20 to 100 micrometers, a microscopic firing range. That's how they form what's called the immunological synapse. It critical. Contact is everything. But here's the technological blind spot, and this is what our deep dive is really all about today.
0:54For decades, when scientists get the tumor micro environment ready for these, you know, high-tech analyses like single cell RNA sequencing. Or flow sitometry. Right. They focus entirely on isolating single cells.
1:06They use these really aggressive enzymes to break all the tissue down, and then they use a technique called single cell gating, to actively throw out anything that looks like a physical clump. I mean, they're essentially treating any of those cell aggregates as just technical noise.
1:22Just a mistake. Yeah, a failure of the preparation. So they systematically remove them just to get clean data for the sequencer. But what if those clumps aren't noise? What if those stable physical clusters are actually the the functional core of the whole immune response?
1:37The T cells that are actively locked onto their targets right in the middle of the fight? If that's true, it means we've been throwing away the most potent, most tumor specific T cells this whole time.
1:48And that changes everything. I mean, it completely changes how we should approach things like adoptive cell therapy. That is the compelling challenge this research tackles. We're exploring a paper that managed to isolate these previously lost clusters.
2:02And, Well, they confirm that these clusters hold a T cell population that is dramatically more powerful than anything we get using our conventional methods. This could really unlock the next generation of cancer therapies.
2:15So let's unpack this. Okay, so today we're celebrating the innovative work led by Sofia Baines Malero, Johanna Veldman, Daniel S. Peeper, and their colleagues. This is a team primarily based at the Netherlands Cancer Institute, which is part of the Encode Institute, and their work was published in nature.
2:32A huge deal. It is. Their research fundamentally advances how we understand these tumor immune cell interactions. They're basically arguing that these cellular aggregates, the clumps, aren't noise. They're the functional units we should have been studying all along.
2:46So to really get the impact here. We need to set the clinical stage. We're talking about treatments like adoptive cell transfer or ACT. When you take T cells out of a patient, grow them up and put them back in.
2:56Exactly. And also immune checkpoint inhibitor therapies, ICIs. The success of both of these, well, revolutionary approaches, it's totally limited by the function and the persistence of the T cells that actually get into the tumor.
3:11If the T cells don't get in there or, and this is the crucial part, if they can't establish and maintain that physical contact, the treatment is going to fail. And that's the paradox, right? We know the T cells are fighting, but the standard lab prep methods, the ones we develop to make the sequencing machines happy.
3:28They were designed to actively destroy the very physical interactions that are necessary for the T cells to function. It's sort of a classic case of the technology getting in the way of the biology. It is, because single cell sequencing requires perfect singlets.
3:42The methodology unintentionally forced us to discard the most biologically relevant structures. So this study, it really aimed to bridge that gap. Between the molecular data and the actual physical fight.
3:53Yes. Their hypothesis was that the physical cluster is the immunological synapse just, you know, captured in the act. So how did they test that? They must have had to completely rethink how they process the 2 samples.
4:05They did. They analyzed 21 human melanoma metastases. which is a really good tumor type to study for this because it's known for having a lot of T cells and responding well to immunotherapy. Okay, so the methodology here is really the star of the show.
4:18They have to bring the tissue down to get the cells out, but they also have to preserve these fragile cell to sell bonds. How on earth did they do that? They did something that sounds simple, but is actually a calculated risk.
4:30They just drastically reduce the enzymatic digestion time. down to a maximum of 30 minutes. Now, less digestion time could mean a lower cell yield, maybe lower viability, but it significantly minimizes the chance that these clusters will break apart.
4:44Okay, so they get these partially digested samples. Then what? Then they hunt for the clusters using flow cytometry. They're looking for what they call double positive events. So, cells that are positive for tumor markers like CD 146, and at the same time positive for 2 cell markers like CD8.
5:01So they're isolating things that look like a T cell stuck to a tumor cell. But, I mean, how do you prove they're really conjugated in a meaningful functional way and not just, you know, some randomly sticky debris?
5:12Ah, and that is where the high resolution visualization comes in. They used a technique called imaging flow psychometry. The image Stream Mark 2 system. That's the one. And this lets them capture incredibly high quality images of 1000s of these clusters.
5:27And with those images, they could actually see the relocalization of adhesion molecules markers. Like HLA, ABC, and CD 58. What does that mean, relocalization? It means these molecules physically moved the exact interface, the point of contact between the 2 cells?
5:44And that only happens when a true immunological synapse is forming. That visual confirmation was the proof. It showed they were isolating stable functional interactions. That's such an elegant bridge. They go from just identifying a clump to confirming it's a functional unit.
5:58Precisely. And once they had that confirmation, they could move on. They separated the T cells that came from these clusters from the T cells that were just found floating around as singlets. And then they subjected both groups to combined single cell RNA sequencing and T cell receptor sequencing.
6:14Which would let them compare the molecular state, and I guess the colonial identity of the T cells, all based on whether they were in a cluster or not. Exactly. And then came the final test function. Could these cells actually kill?
6:25They tested them in the lab against the patient's own melanoma cells, and then the ultimate test, in vivo, using adoptive cell transfer and humanized mouse models. And the results, I take it, were pretty definitive.
6:37Absolutely. They completely supported this idea that we've been missing the functional epicenter of the immune response. So finding number one. Finding one was just establishing that this clustering isn't rare.
6:48It's universal. They successfully isolated these heterotypic clusters, CD8 plus T cells, bound to tumor cells or to antigen presenting cells, APCs, from every single one of the 21 human melanoma samples they looked at.
7:01Wow, all 21. So this is happening all the time in the tumor. It's a pervasive phenomena. But are the clusters just, you know, random sticking. Or are they actually driven by specific antigen recognition?
7:13That seems like the next critical question. And they address that with this really elegant in vitro competition assay. They co-cultured T cells that were specific for a known melanoma antigen, Mark one with a bunch of non-specific T cells.
7:30Okay, so a mix of specialist and non-specialist cell. Right. And they found that the antigen specific T cells just dramatically outcompeted the others at forming clusters. And think about this ratio. Even when the specific T cells made up only one% of the total T cell pool.
7:45Just one percent. They were up to 11 fold enriched in the clusters they isolated. 11 times enrichment from such a tiny starting fraction. I mean, that magnitude pretty much proves these physical interactions are driven by specific high affinity recognitions, not random.
7:58And now for the key therapeutic implication. T cells that they isolated from these clusters. When they were expanded using a standard protocol, they showed an average ninefold increased healing activity.
8:10Rainfold. A ninefold increase against the patient's own melanoma cells compared to T cells that were expanded from the singlet pool. This wasn't a small gain. It was a profound increase in lethality. And it correlated with more of those key cytotoxic cytokines like Interfere on Gamma and TNF.
8:28A 9 times boost in killing power just by changing how you select the cells from single cells to physical clusters. That's well, that's transformational for ACT development. And this improved function held up in Vivo, too.
8:40In the mouse models with human melanomas, the T cells from the clusters successfully and significantly suppressed tumor growth. And the T cells from the singlets. These showed essentially no tumor control.
8:50The cluster derived cells were validated as superior therapeutic agents across the board. They saw more T cell infiltration, more activation of the tumor site, everything pointed in the same direction.
9:00Okay, so the central question then becomes, what is it about these cells? What's their molecular identity? Why are that such superior killers? The CRNASEC data gave a fascinating answer to that. The clustered T cells were highly enriched for gene signatures related to both tumor reactivity and kind of paradoxically exhaustion.
9:21Right, and also proliferation markers, but why would we be excited about exhausted T cells? That sounds bad. Well, in the context of a solid tumor, exhaustion is often a sign of active, prolonged engagement.
9:33I see. The T cells that have been fighting the longest, the ones that are the most clonely expanded, they often get categorized as exhausted. But they aren't necessarily useless. They're more like fatigued warriors.
9:44The goal in immunotherapy is often to find these very specific exhausted cells and then rearm them outside the body. They're the veterans of the fight, not the fresh recruits. That's a great way to put it.
9:54Now, the researchers also drill down even further. They compare T sales clustered with tumor cells versus T cells clustered with APCs. And this gives us a window into the whole dynamic process of immune attack and regulation.
10:07What do they find? They found this critical functional split. They looked at T cells that had the exact same T cell receptor, so they came from the same anti-tumor club. Yeah. But their behavior change completely depending on their partner.
10:19Okay. When they were conjugated to antigen presenting cells APCs, like certain macrophages or dendritic cells, those T cells showed a very distinct phenotype. Which was? They showed more pronounced exhaustion markers.
10:34They were heavily involved in these co-modulatory interactions, like PD1 binding to PDL1, or CTLA 4 interacting with CD28. Ah, so the immune checkpoint. Exactly. It suggests the ABC interaction might be regulatory.
10:48It could be involved in the initial priming or maybe dampening the T cell response to prevent overreaction. It's an immune checkpoint in action. So if the T cell is the fighter jet, the APC is kind of like the pit crew regulating it.
11:00That's it, exactly. Conversely, when those identical T cell clones were found stuck directly to the tumor cells, they look different. They showed fewer exhaustion markers and way more of these strong adhesion interactions.
11:11Like ICam one, ITGL. Those were hallmarks of sustained cytotoxic engagement. That phenotype is consistent with a T cell that's actively in the process of delivering the killing blow. That detail is phenomenal.
11:25It shows the physical context defines the cell's role, even within the very same clone. So, let's bring this back to the clinic. Can selecting for these clusters replace our current methods for ACT? I think that's the biggest implication.
11:38Right now, enrichment strategies for ACT often rely on sorting for a single marker like CD 39, which is often found on tumor reactive T cells. But when the researchers benchmarked cluster sorting against the standard single cell CD 39 plus sorting.
11:52The results were just staggering. How bad was it? Single cell gating for CD 39 plus caused a 91% loss of the functional T cell tumor clusters. 91%. So we've been throwing away 9 out of every 10 of the most promising cells.
12:05And the reason for this systemic failure. It lies in the underlying molecular state of the cells. The T cells they isolated from the clusters were profoundly enriched for what's called a TCF 7 plus stem-like, exhausted cell state.
12:19And this is the cell population that is absolutely critical for ACT success. Okay, walk us through that. Why is that TCF 7+ state the golden ticket? So TCF 7 is a transcription factor. It's associated with stemness with self-renewal.
12:32T cells that maintain this TCF 7 plus state are the ones that can persist long term in vivo after they're infused. They keep their ability to proliferate. They're the fountain of youth for therapy. Exactly.
12:42In contrast, when you sort just for markers like CD 39, you often end up selecting for T cells that are terminally exhausted. These are cells that are high in markers like LAG 3 and they've lost their TCF 7 expression.
12:54These cells, they just burn out really quickly. You get very limited therapeutic success. So the standard method selects for cells that are basically programmed to fail in the long run. While the cluster isolation method, it selects for the self-renewing, persistent T cells.
13:08This reframes the entire paradigm for how you generate clinically effective T cell therapies. The message is just so clear. The physical cluster is not technical noise. It's a phenotypic fingerprint of the most highly functional, long-lasting anti-tumor response that's available.
13:24These clusters contain the elite TCF 7 plus stem like fighters that we need for durable remissions. This research really does dramatically reframe how we have to approach tissue analysis in amino oncology.
13:38We have to shift from a focus on, you know, molecular purity to prioritizing functional cellular architecture. The central insight is that these stable physical clusters of CD8 plus T cells and their targets, they are the functional epicenter of the anti-tumor response.
13:53And not only are these closer T cells far more potent, we're talking a ninefold increase in killing activity, but they're enriched for that specific molecular profile. That TCF 7 plus stem-like state that is absolutely essential for long-term therapeutic persistence and success in adoptive cell transfer.
14:08And when you consider that the unique gene signature of these clustered T cells was also found to predict patient response to existing TIL therapy, Well, that has immediate diagnostic relevance. It leaves you with a really thought provoking prompt.
14:21How quickly can we integrate the detection of these specific molecular profiles, these signatures of cluster T cells into our diagnostics, to figure out who is likely to benefit most from immunotherapies before they even start treatment?
14:34That predictive power is something to truly mull over. This episode was based on an open access article under the CCBY 4.0 license. You can find a direct link to the paper and the license in our episode description.
14:47If you enjoyed this, follow or subscribe in your podcast app and leave a 5 star rating. If you'd like to support our work, use the donation link in the description. Now stay with us for an original track created, especially for this episode, and inspired by the article you've just heard about.
15:01Thanks for listening, and join us next time as we explore more science, base by base.
